An ongoing phase 2 trial (NCT03802123) will test both the diagnostic performance and the predictive performance of 89Zr-Df-IAB22M2C, by correlating CD8 signal on PET/CT imaging to CD8+ T-cell infiltration from biopsy samples, and response to cancer immunotherapy, respectively. This evidence concerns the gene CD8A and cancer.